Sunvozertinib — drug · CancerIndex

Drug · Small Molecule

Sunvozertinib

CI-DRUG-00000565Explore in graph →NCIt C167205 CHEMBL5314564 CIViC Phase 3

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	12	8	2	13	0	—	—	Jul 9, 2019
Malignant Lung Neoplasm	Phase3	Phase 3	12	8	2	12	0	—	—	Jul 9, 2019
Non-Hodgkin Lymphoma	Phase2	Phase 2	0	0	0	1	0	—	—	2021-08

Computedclinicaltrials

Curated evidence

Clinical evidence (7)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–7 of 7 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR A767_S768insTLA + EGFR D770delinsAS + EGFR D770delinsGY + EGFR D770_N771insY + EGFR H773_V774insGNPH + EGFR N771_P772insT + EGFR S768_V769insLDS + EGFR V769_D770insCV + EGFR V769_D770insGA + EGFR V769_D770insGVASV

Clinical trials

Trials with this intervention (14)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–14 of 14 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05559645	Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)(WU-KONG15)	recruiting	N/A	180	Peking Union Medical College HospitalOTHER	1	Sep 2, 2026	clinicaltrials
NCT07079475	Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

EGFR D770_N771insD + EGFR D770_N771insF + EGFR D770_N771insGD + EGFR D770_N771insGT + EGFR D770_N771insT + EGFR N771delinsCH + EGFR N771delinsGF + EGFR N771delinsRD + EGFR N771delinsSQRGH + EGFR N771_P772insDN1
Sunvozertinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID12632 In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC) PMID 40923280 · Yang et al., 2025 · Open in CIViC	civic

EGFR Exon 20 Insertion1
Sunvozertinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID12718 In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC) PMID 40923280 · Yang et al., 2025 · Open in CIViC	civic

EGFR C775_R776insNPHVC + EGFR H773delinsYNPY + EGFR H773delinsYPNPY + EGFR H773_V774insHPH + EGFR H773_V774insTH1
Sunvozertinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID12634 In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC) PMID 40923280 · Yang et al., 2025 · Open in CIViC	civic

EGFR A763_Y764insFQEA + EGFR D770_N771insG + EGFR D770_N771insH + EGFR H773_V774insAH + EGFR H773_V774insH + EGFR H773_V774insNPH + EGFR H773_V774insPH + EGFR N771dup + EGFR V774_C775insHV1
Sunvozertinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID12630 In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC) PMID 40923280 · Yang et al., 2025 · Open in CIViC	civic

EGFR H773delinsNPY + EGFR H773delinsPNPY + EGFR N771delinsGY + EGFR N771_P772insRH + EGFR N771_P772insVDN + EGFR P772delinsHR + EGFR P772_H773insDNP + EGFR P772_H773insPHP + EGFR P772_H773insQ + EGFR P772_H773insRNP + EGFR P772_H773insYNP1
Sunvozertinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID12633 In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC) PMID 40923280 · Yang et al., 2025 · Open in CIViC	civic

EGFR A767_V769dupASV + EGFR S768_D770dup1
Sunvozertinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID12623 In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC) PMID 40923280 · Yang et al., 2025 · Open in CIViC	civic